Accrual and retention of diverse patients in psychosocial cancer clinical trials

Grace Ann Hanvey, Adaixa Padron, Elizabeth L Kacel, Gabriel Cartagena, Kelsey C Bacharz, Christina S McCrae, Michael E Robinson, Lori B Waxenberg, Michael H Antoni, Richard B Berry, Gregory S Schultz, Jacqueline Castagno, Deidre B Pereira, Grace Ann Hanvey, Adaixa Padron, Elizabeth L Kacel, Gabriel Cartagena, Kelsey C Bacharz, Christina S McCrae, Michael E Robinson, Lori B Waxenberg, Michael H Antoni, Richard B Berry, Gregory S Schultz, Jacqueline Castagno, Deidre B Pereira

Abstract

Background: Minority and older adult patients remain underrepresented in cancer clinical trials (CCTs). The current study sought to examine sociodemographic inequities in CCT interest, eligibility, enrollment, decline motivation, and attrition across two psychosocial CCTs for gynecologic, gastrointestinal, and thoracic cancers.

Methods: Patients were approached for recruitment to one of two interventions: (1) a randomized control trial (RCT) examining effects of a cognitive-behavioral intervention targeting sleep, pain, mood, cytokines, and cortisol following surgery, or (2) a yoga intervention to determine its feasibility, acceptability, and effects on mitigating distress. Prospective RCT participants were queried about interest and screened for eligibility. All eligible patients across trials were offered enrollment. Patients who declined yoga intervention enrollment provided reasons for decline. Sociodemographic predictors of enrollment decisions and attrition were explored.

Results: No sociodemographic differences in RCT interest were observed, and older patients were more likely to be ineligible. Eligible Hispanic patients across trials were significantly more likely to enroll than non-Hispanic patients. Sociodemographic factors predicted differences in decline motivation. In one trial, individuals originating from more urban areas were more likely to prematurely discontinue participation.

Discussion: These results corroborate evidence of no significant differences in CCT interest across minority groups, with older adults less likely to fulfill eligibility criteria. While absolute Hispanic enrollment was modest, Hispanic patients were more likely to enroll relative to non-Hispanic patients. Additional sociodemographic trends were noted in decline motivation and geographical prediction of attrition. Further investigation is necessary to better understand inequities, barriers, and best recruitment practices for representative CCTs.

Keywords: Cancer; clinical trials; health disparities; recruitment; retention.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

© The Author(s) 2022.

References

    1. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. The Journal of the American Medical Association 2004; 291(22): 2720. DOI 10.1001/jama.291.22.2720.
    1. Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. American Society of Clinical Oncology Educational Book 2016; 35: 185–198. DOI 10.1200/edbk_156686.
    1. Byrne MM, Tannenbaum SL, Glück S, Hurley J, Antoni M. Participation in cancer clinical trials: why are patients not participating? Medical Decision Making 2014; 34(1): 116–126. DOI 10.1177/0272989X13497264.
    1. Flores G, Portillo A, Lin H, et al. A successful approach to minimizing attrition in racial/ethnic minority, low-income populations. Contemporary Clinical Trials Communications 2017; 5(6): 168–174. DOI 10.1016/j.conctc.2017.01.009.
    1. Wallington SF, Dash C, Sheppard VB, et al. Enrolling minority and underserved populations in cancer clinical research. American Journal of Preventive Medicine 2016; 50(1): 111–117. DOI 10.1016/j.amepre.2015.07.036.
    1. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008; 112(2): 228–242. DOI 10.1002/cncr.23157.
    1. Napoles A, Cook E, Ginossar T, Knight KD, Ford ME. Applying a conceptual framework to maximize the participation of diverse populations in cancer clinical trials. Advances in Cancer Research 2017; 133(6): 77–94. DOI 10.1016/bs.acr.2016.08.004.
    1. Durant RW, Wenzel JA, Scarinci IC, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer 2014; 120(7): 1097–1105. DOI 10.1002/cncr.28574.
    1. Echeverri M, Anderson D, Nápoles AM, Haas JM, Johnson ME, Serrano FSA. Cancer health literacy and willingness to participate in cancer research and donate bio-specimens. International Journal of Environmental Research and Public Health 2018; 15(10): 2091. DOI 10.3390/ijerph15102091.
    1. Joseph G, Dohan D. Recruiting minorities where they receive care: institutional barriers to cancer clinical trials recruitment in a safety-net hospital. Contemporary Clinical Trials 2009; 30(6): 552–559. DOI 10.1016/j.cct.2009.06.009.
    1. Niranjan SJ, Martin MY, Fouad MN, et al. Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials. Cancer 2020; 126(9): 1958–1968. DOI 10.1002/cncr.32755.
    1. Kwiatkowski K, Coe K, Bailar JC, Swanson GM. Inclusion of minorities and women in cancer clinical trials, a decade later: have we improved? Cancer 2013; 119(16): 2956–2963. DOI 10.1002/cncr.28168.
    1. Cunningham-Erves J, Mayo-Gamble TL, Hull PC, et al. A pilot study of a culturally-appropriate, educational intervention to increase participation in cancer clinical trials among African Americans and Latinos. Cancer Causes Control 2021; 32(9): 953–963. DOI 10.1007/s10552-021-01449-7.
    1. Niranjan SJ, Durant RW, Wenzel JA, et al. Training needs of clinical and research professionals to optimize minority recruitment and retention in cancer clinical trials. Journal of Cancer Education 2019; 34(1): 26–34. DOI 10.1007/s13187-017-1261-0.
    1. Rivers D, August EM, Sehovic I, Lee Green B, Quinn GP. A systematic review of the factors influencing African Americans’ participation in cancer clinical trials. Contemporary Clinical Trials 2013; 35(2): 13–32. DOI 10.1016/j.cct.2013.03.007.
    1. Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Annals of Surgical Oncology 2007; 14(12): 3328–3334. DOI 10.1245/s10434-007-9500-y.
    1. Zuniga K, Borno H, Chan J, et al. The problem of underrepresentation: black participants in lifestyle trials among patients with prostate cancer. Journal of Racial and Ethnic Health Disparities 2020; 7(5 PG-996-1002): 996–1002. DOI 10.1007/s40615-020-00724-8.
    1. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Research 1989; 28(2): 193–213. DOI 10.1016/0165-1781(89)90047-4.
    1. Edinger JD, Bonnet MH, Bootzin RR, et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine work group. Sleep 2004; 27(8): 1567–1596. DOI 10.1093/sleep/27.8.1567.
    1. Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: psychometric properties of a self-report version. Journal of Clinical Psychology 1988; 44(4): 499–505. DOI 10.1002/1097-4679(198807)44:4<499::AID-JCLP2270440404>;2-6.
    1. Spitzer RL, Williams JBW, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID): I: history, rationale, and description. Archives of General Psychiatry 1992; 49(8): 624–629. DOI 10.1001/archpsyc.1992.01820080032005.
    1. Singh S, Bajorek B. Defining, elderly, in clinical practice guidelines for pharmacotherapy. Pharmacy Practice 2014; 12(4): 489. DOI 10.4321/s1886-36552014000400007.
    1. US Census Bureau. The Demographic Statistical Atlas of the United States - Statistical Atlas, 2018. Statistical Atlas.
    1. Singh-Manoux A, Adler NE, Marmot MG. Subjective social status: its determinants and its association with measures of ill-health in the Whitehall II study. Social Science & Medicine 2003; 56(6): 1321–1333. DOI 10.1016/S0277-9536(02)00131-4.
    1. Berzofsky M, Smiley-McDonald H, Moore A, Krebs C. Measuring socioeconomic status (SES) in the NCVS: background, options, and recommendations. Bureau of Justice Statistics U.S. Department of Justice 2014, 1–59. DOI 10.1007/BF03061070.
    1. Ingram D, Franco S. 2013 NCHS urban-rural classification scheme for counties. Vital and Health Statistics Reports 2014; 2(166): 1–73.
    1. Tobias KG, Lehrfeld J, Rosenfeld B, Pessin H, Breitbart W. Confirmatory factor analysis of the beck depression inventory-II in patients with advanced cancer: a theory-driven approach. Palliative & Supportive Care 2017; 15(6): 704–709. DOI 10.1017/S1478951517000724.
    1. Mystakidou K, Tsilika E, Parpa E, Sakkas P, Vlahos L. The psychometric properties of the greek version of the state-trait anxiety inventory in cancer patients receiving palliative care. Psychology & Health 2009; 24(10): 1215–1228. DOI 10.1080/08870440802340172.
    1. Spielberger C. State-trait anxiety inventory for adults. 1983. [Database record].
    1. Katz J, Melzack R. The McGill pain questionnaire: development, psychometric properties, and usefulness of the long-form, short-form, and short-form-2. In: Turk DC, Melzac R, eds. Handbook of Pain Assessment. The Guillford Press; 2011: 45–66.
    1. Lovejoy TI, Turk DC, Morasco BJ. Evaluation of the psychometric properties of the revised short-form McGill pain questionnaire. The Journal of Pain 2012; 13(12): 1250–1257. DOI 10.1016/j.jpain.2012.09.011.
    1. Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain 1975; 975(3): 277–299. DOI 10.1016/0304-3959(75)90044-5.
    1. Graham C, Bond SS, Gerkovich MM, Cook MR. Use of the McGill pain questionaire in the assessment of cancer pain: replicability and consistency. Pain 1980; 8(3): 377–387. DOI 10.1016/0304-3959(80)90081-0.
    1. Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A. Psychometric evaluation of the Pittsburgh sleep quality index in cancer patients. Journal of Pain and Symptom Management 2004; 27(2): 140–148. DOI 10.1016/j.jpainsymman.2003.12.002.
    1. Akman T, Yavuzsen T, Sevgen Z, Ellidokuz H, Yilmaz AU. Evaluation of sleep disorders in cancer patients based on Pittsburgh sleep quality index. European Journal of Cancer Care 2015; 24(4): 553–559. DOI 10.1111/ecc.12296.
    1. Goodwin PJ, Leszcz M, Quirt G, et al. Lessons learned from enrollment in the BEST study - A multicenter, randomized trial of group psychosocial support in metastatic breast cancer. Journal of Clinical Epidemiology 2000; 53(1): 47–55. DOI 10.1016/S0895-4356(99)00148-1.
    1. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. Journal of Clinical Oncology 2005; 23(13): 3112–3124. DOI 10.1200/JCO.2005.00.141.
    1. Hugo J, Ganguli M. Dementia and cognitive impairment. epidemiology, diagnosis, and treatment. Clinics in Geriatric Medicine 2014; 30(3): 421–442. DOI 10.1016/j.cger.2014.04.001.
    1. Gooneratne NS, Vitiello MV. Sleep in older adults. normative changes, sleep disorders, and treatment options. Clinics in Geriatric Medicine 2014; 30(3): 591–627. DOI 10.1016/j.cger.2014.04.007.
    1. Dautovich ND, McCrae CS, Rowe M. Subjective and objective napping and sleep in older adults: are evening naps, bad, for nighttime sleep? Journal of the American Geriatrics Society 2008; 56(9): 1681–1686. DOI 10.1111/j.1532-5415.2008.01822.x.
    1. Aizer AA, Wilhite TJ, Chen MH, et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 2014; 120(10): 1532–1539. DOI 10.1002/cncr.28617.
    1. Levit L, Byatt L, Lyss A, et al. Closing the rural cancer care gap: three institutional approaches. Journal of Oncology Practice 2020; 16(7): 422–431. DOI 10.1200/OP.20.00174.
    1. Sateren W, Trimble E, Abrams J, Brawley O, Breen N, Ford L. How sociodemographics, presence of oncolofy specialists, and hospital cancer programs affect accrual to cancer treatment trials. Journal of Clinical Oncology 2002; 20(8): 2109–2116. DOI 10.1200/JCO.2002.08.056.
    1. Salman A, Nguyen C, Lee YH, Cooksey-James T. A review of barriers to minorities’ participation in cancer clinical trials: implications for future cancer research. Journal of Immigrant and Minority Health 2016; 18(2): 447–453. DOI 10.1007/s10903-015-0198-9.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться